Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

When are placebo-controlled trials no longer appropriate?

B A Brody1

  • 1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas 77030, USA.

Controlled Clinical Trials
|December 31, 1997
PubMed
Summary

This study introduces an ethical standard for placebo-controlled trials, ensuring patient safety by categorizing acceptable risks for control groups. It demonstrates how to conduct essential research while upholding ethical guidelines, using thrombolytic agent trials as examples.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethics and methods in surgical trials.

Journal of medical ethics·2009
Same author

Making informed consent meaningful.

IRB·2003
Same author

Placebos in clinical trials: new forms of an old issue.

Health law news. University of Houston. Health Law and Policy Institute·2003
Same author

Effects of storage and viral load on hepatitis C viral genotyping.

Journal of clinical laboratory analysis·2002
Same author

The prevalence of female genital operations in the Houston metropolitan area.

Texas medicine·2001
Same author

A national survey of policies on disclosure of conflicts of interest in biomedical research.

The New England journal of medicine·2000

Area of Science:

  • Clinical Trials
  • Medical Ethics
  • Cardiology

Background:

  • Placebo-controlled trials are crucial for drug efficacy assessment.
  • Ethical concerns arise when placebo groups may be denied effective treatments.
  • Thrombolytic agent trials highlight these ethical dilemmas.

Purpose of the Study:

  • To propose a standard for evaluating placebo-controlled trials ethically.
  • To define acceptable risk levels for participants in control groups.
  • To ensure ethical conduct of clinical research without compromising patient welfare.

Main Methods:

  • Developed a risk categorization framework for research subjects.
  • Applied the standard to analyze major thrombolytic agent trials.
  • Illustrated ethical considerations in clinical trial design.

Related Experiment Videos

Main Results:

  • A clear standard for assessing the ethical validity of placebo-controlled trials was established.
  • The framework differentiates between permissible and impermissible risks for control groups.
  • Demonstrated feasibility of conducting necessary research under the proposed ethical standard.

Conclusions:

  • The proposed standard provides a robust ethical framework for placebo-controlled trials.
  • It balances the need for rigorous scientific inquiry with the protection of research participants.
  • Ethical trial design is achievable, even in complex therapeutic areas like cardiology.